Biotechnology · Watertown, Massachusetts, United States
$4.20
+0.24% (+$0.01)2026-07-09
Smart-Money SignalNeutral · 50/100— Insiders are net buyers over 90 days ($28K, 4 buys vs 1 sale)
Revenue$6.2M
Net Income-$25.1M
EPS$-0.20
Market Cap$437.0M
Price Performance
Historical data including institutional events
Company Profile
A
Andrew Hirsch
CEO & Executive Director
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration.
It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
